Description
RMC-5127 is a selective KRAS G12C inhibitor designed for treatment of colorectal cancer patients harboring the KRAS G12C mutation. This oral small molecule therapy targets tumors with specific genetic alterations that drive cancer cell growth and proliferation.
Mechanism of Action
The drug works by covalently binding to the KRAS G12C mutant protein, locking it in an inactive state and preventing downstream signaling pathways that promote tumor growth. This targeted approach disrupts cellular proliferation and can lead to tumor regression in KRAS G12C-positive colorectal cancers.
Side Effects
Diarrhea
Fatigue
Nausea
Decreased appetite
Abdominal pain
Vomiting
Constipation
Rash
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT07349537
Phase 1
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
United States